Sanofi pays $45m for early look-in on genetic heart disease program
This article was originally published in Scrip
Sanofi has paid $45m via an upfront licensing fee and equity investment in young South San Francisco-based biotech MyoKardia, which is developing targeted therapies for genetic heart disease. The collaboration is an outgrowth of Sanofi's Sunrise initiative, a partnership model focused on early stage opportunities.
You may also be interested in...
Biotech regains full rights to a pair of targeted therapies for heart diseases, but will bear full development costs. MyoKardia says the agreement with Sanofi ended due to differences over commercial rights, not concerns about trial data.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.